vendredi 3 juin 2016

Onco Actu du 3 juin 2016

1. Biologie

New CRISPR system for targeting RNA [MIT News]

RNA-Targeting CRISPR [The Scientist]

2. Etiologie

Talc linked to ovarian cancer risk in African-American women [Reuters]

4.10 Dép., diag. & prono. - Poumon

Risk Profiling May Improve Lung Cancer Screening [National Cancer Institute]

5. Traitements

Could statins prevent breast cancer returning? [NHS Choices]

5.10 Traitements - Essais

Assessing the Gold Standard — Lessons from the History of RCTs [NEJM]

Errors in the NEJM’s portrayal of Randomized Controlled Trials [Vinay Prasad MD]

5.12 Immunothérapies

Research raises hope of a 'Holy Grail' universal cancer vaccine [NHS Choices]

Let the right ones in – boosting immunotherapy for pancreatic cancer [Cancer Research UK]

Scientists 'tear down' pancreatic cancer defences in trial [The Telegraph]

5.12.2 Immunothérapies - CAR-T

Kite Pharma and Cell Design Labs Announce Exclusive Research Collaboration Using Molecular ‘On/Off Switches' for CAR T-Cell Immunotherapies [KITE]

5.2 Pharma

Are Things Getting Any Better in the Clinic? [In the Pipeline]

A Decade of Innovation in Cancer 2006-2016 [Phrma]

5.3 Traitements - FDA, EMA,...

Science, not public opinion, should rule FDA drug approvals [STAT]

Statement from FDA Commissioner Robert Califf, M.D. on the release of the final individual patient expanded access form [FDA]

5.4 Traitements - Economie

We’re spending $107 billion on cancer drugs, but is it worth it? [Washington Post]

Sharp rise in cancer drug spending forecast, but access remains a problem [STAT]

Global Oncology Trend Report a Review of 2015 and Outlook to 2020 [IMS Health]

5.5 ASCO

Thomson Reuters Launches New Precision Medicine Intelligence [PR Newswire]

5.5.1 ASCO (général)

EORTC Presentations at ASCO 2016 in Chicago [EORTC] ASCO (général) - Industriels

Immunomedics Breast Cancer Drug Kicked Out of Prestigious ASCO Cancer Conference [The Street]

5.5.13 ASCO (divers)

Why Cancer Patients And Doctors Should Rethink The Value Of Phase 1 Trials [Forbes]

5.5.4 ASCO (immunothérapies)

Promising drugs stoke talk of eventual cancer 'cure' [Reuters]

6. Lutte contre les cancers

Risks of X-rays for cancer diagnosis may be a mystery to most patients [Reuters]

Mindfulness program may reduce fear, fatigue for cancer survivors [Reuters]

6.1 Observation

Cancer Survivors: A Growing Population [ACS]

6.10 Politiques

California moves closer to requiring drug makers to justify price hikes [STAT]

6.11 Patients

Well: An Artist Takes On Cancer [NY Times]

6.5 Médecines alternatives

False “balance” about Stanislaw Burzynski’s cancer quackery rears its ugly head again [Respectful Insolence]

6.7 DMP, Big Data & applis

CancerLinQ Launches New and Improved Website [ASCO]

6.9 Controverses

Plan to synthesize human genome elicits mixed response [Nature News & Comment]

Plan to Fabricate a Genome Raises Questions on Designer Humans [MIT Technology Review]